Voclosporin for the treatment of lupus nephritis

被引：0
|
作者：
Dolff, Sebastian [1 ]
机构：
[1] Univ Duisburg Essen, Univ Med Essen, Klin Infektiol, Hufelandstr 55, D-45122 Essen, Germany
来源：
NEPHROLOGIE | 2022年 / 17卷 / 05期
关键词：
INDUCTION;
D O I：
10.1007/s11560-022-00596-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：334 / 338
页数：5
相关论文
共 50 条
  • [31] Voclosporin Induces Systemic Lipidomic Alterations: Implications in the Remission of Lupus Nephritis
    Afshinnia, Farsad
    Rehaume, Linda M.
    Cross, Jennifer
    Huizinga, Robert B.
    Pennathur, Subramaniam
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 792 - 792
  • [32] Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
    Saxena, Amit
    Mela, Christopher
    Coeshall, Antonia
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2990 - 2993
  • [33] Voclosporin Is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis
    Menn-Josephy, Hanni
    Truman, Matt
    Palmen, Mary
    Mina-Osorio, Paola
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 48 - 48
  • [34] Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis Remission
    Afshinnia, Farsad
    Rajendiran, Thekkelnaycke M.
    Byun, Jaeman
    Arnipalli, Manikanta Swamy
    Rehaume, Linda M.
    Cross, Jennifer L.
    Huizinga, Robert B.
    Pennathur, Subramaniam
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (08): : 2559 - 2562
  • [35] VOCLOSPORIN FOR LUPUS NEPHRITIS: INTERIM ANALYSIS OF THE AURORA 2 EXTENSION STUDY
    Saxena, A.
    Mina-Osorio, P.
    Mela, C.
    Berardi, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 585 - 586
  • [36] Disease Targeting Properties of Voclosporin in Kidney Transplant and Lupus Nephritis Patients
    Zhou, Simon
    Rehaume, Linda M.
    Yap, Ernie
    Leher, Henry
    Hodge, Lucy S.
    Huizinga, Robert B.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [37] VOCLOSPORIN INHIBITS CALCINEURIN AND T CELL ACTIVATION AT DOSE LEVELS CLINICALLY RELEVANT FOR THE TREATMENT OF LUPUS NEPHRITIS
    Rehaume, Linda M.
    Cross, Jennifer L.
    Hulzinga, Robert B.
    Viel, John J.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S97 - S97
  • [38] Efficacy and Safety of Voclosporin Over 3 Years in Patients With Severe Lupus Nephritis
    Menn-Josephy, Hanni
    Truman, Matt
    Palmen, Mary
    Leher, Henry
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 33 - 33
  • [39] The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States
    Mandrik, Olena
    Fotheringham, James
    Ren, Shijie
    Tice, Jeffrey A.
    Chapman, Richard H.
    Stevenson, Matthew D.
    Pearson, Steven D.
    Herron-Smith, Serina
    Agboola, Foluso
    Thokala, Praveen
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03): : 385 - 394
  • [40] CONFIRMATION OF THE IMMUNOSUPPRESSIVE FUNCTION OF VOCLOSPORIN AT THE CLINICALLY RELEVANT LUPUS NEPHRITIS DOSE IN LUPUS-PRONE MICE
    Rehaume, Linda M.
    Cross, Jennifer L.
    Huizinga, Robert B.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S41 - S41
12345